Abera Bioscience reported a positive Q1 2025 net result, driven by grant income and progress in vaccine R&D, with strong preclinical data and regulatory support for clinical trials. Continued funding from CEPI and UK Vaccine Network secures operations.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.